LFCR (Lifecore Biomedical) Current Deferred Revenue: $5.86 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LFCR Lifecore Biomedical Inc LFCR
56 GF Score
Price $4.34
GF Value $6.46
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Current Deferred Revenue?

Lifecore Biomedical LFCR -2.26% 56 Current Deferred Revenue is $5.86 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 56/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Lifecore Biomedical's current deferred revenue for the quarter that ended in Mar. 2026 was $5.86 Mil.

Lifecore Biomedical Current Deferred Revenue Related Terms

Lifecore Biomedical Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Current Deferred Revenue Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.92 4.06 2.11 3.42

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 3.42 7.21 8.66 5.86
LFCR
56GF Score
Lifecore Biomedical Inc LFCR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $5.86 Mil mean?
Lifecore Biomedical (LFCR) has a Current Deferred Revenue of $5.86 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Current Deferred Revenue too high?
Lifecore Biomedical's current Current Deferred Revenue is $5.86 Mil. Overall, Lifecore Biomedical has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Current Deferred Revenue compare to ANIK and DERM?
Lifecore Biomedical's Current Deferred Revenue of $5.86 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Current Deferred Revenue is $5.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $4.34 — trading 32.8% below its estimated fair value. The current Current Deferred Revenue is $5.86 Mil. Lifecore Biomedical's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Current Deferred Revenue is $5.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.34 is trading 32.8% below its estimated GF Value™ of $6.46. GuruFocus considers Lifecore Biomedical to be Possible Value Trap.

Key valuation signals for LFCR:

  • Current Deferred Revenue: $5.86 Mil
  • GF Value™: $6.46 vs. price of $4.34 (32.8% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
56GF Score

Get the complete analysis for LFCR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.34
Price
$6.46
GF Value